Lay abstract Inflammation and malnutrition in cancer patients may affect the immune system and response to therapy. We noticed an increase in inflammation and visceral fat and a decrease in muscle and subcutaneous fat during therapy. No variation showed a significant correlation with survival. Muscle mass, adipose tissue and body mass index do not confirm any prognostic impact or relationship with response to therapy. More interesting results were observed with parameters related to inflammation. Probably, for the best treatment choice, a combination of clinical and biological factors will be necessary. Further studies with a multidimensional approach are needed to propose the best treatment and the best support to everyone.Tweetable abstract Body composition, nutritional and inflammatory status changed during first-line immunotherapy on NSCLC patients. Inflammation has interesting prognostic implications. Combined with other factors, these clinical characteristics may be important to optimize the care of patients.Background: Immunotherapy changed the landscape of non-small cell lung cancer (NSCLC). Efforts were made to implement its action. This study aims to describe body composition, nutritional and inflammatory status in NSCLC patients treated by first-line immunotherapy, their correlation, variation and impact. Patients and methods: We retrospectively analyzed 44 consecutive patients who received pembrolizumab treatment. Results: During the therapy, inflammation and visceral fat increased, whereas muscle and subcutaneous fat decreased. Parameters related to inflammation had an interesting prognostic impact. High numbers of white blood cells remained significantly correlated with a high risk of death in multivariate model. Conclusion: For the best treatment choice, a combination of clinical and biological factors will be most likely be necessary. Prospective and larger studies with a multidimensional approach are needed.

Body composition and inflammation impact in non-small cell lung cancer patients treated by first-line immunotherapy / Baldessari, Cinzia; Pecchi, Annarita; Marcheselli, Raffaella; Guaitoli, Giorgia; Bonacini, Riccardo; Valoriani, Filippo; Torricelli, Pietro; Reverberi, Linda; Menozzi, Renata; Pugliese, Giuseppe; Vitale, Maria Giuseppa; Sabbatini, Roberto; Bertolini, Federica; Barbieri, Fausto; Dominici, Massimo. - In: IMMUNOTHERAPY. - ISSN 1750-743X. - 13:18(2021), pp. 1501-1519. [10.2217/imt-2021-0038]

Body composition and inflammation impact in non-small cell lung cancer patients treated by first-line immunotherapy

Baldessari, Cinzia;Pecchi, Annarita;Marcheselli, Raffaella;Guaitoli, Giorgia;Bonacini, Riccardo;Torricelli, Pietro;Reverberi, Linda;Menozzi, Renata;Pugliese, Giuseppe;Bertolini, Federica;Dominici, Massimo
2021

Abstract

Lay abstract Inflammation and malnutrition in cancer patients may affect the immune system and response to therapy. We noticed an increase in inflammation and visceral fat and a decrease in muscle and subcutaneous fat during therapy. No variation showed a significant correlation with survival. Muscle mass, adipose tissue and body mass index do not confirm any prognostic impact or relationship with response to therapy. More interesting results were observed with parameters related to inflammation. Probably, for the best treatment choice, a combination of clinical and biological factors will be necessary. Further studies with a multidimensional approach are needed to propose the best treatment and the best support to everyone.Tweetable abstract Body composition, nutritional and inflammatory status changed during first-line immunotherapy on NSCLC patients. Inflammation has interesting prognostic implications. Combined with other factors, these clinical characteristics may be important to optimize the care of patients.Background: Immunotherapy changed the landscape of non-small cell lung cancer (NSCLC). Efforts were made to implement its action. This study aims to describe body composition, nutritional and inflammatory status in NSCLC patients treated by first-line immunotherapy, their correlation, variation and impact. Patients and methods: We retrospectively analyzed 44 consecutive patients who received pembrolizumab treatment. Results: During the therapy, inflammation and visceral fat increased, whereas muscle and subcutaneous fat decreased. Parameters related to inflammation had an interesting prognostic impact. High numbers of white blood cells remained significantly correlated with a high risk of death in multivariate model. Conclusion: For the best treatment choice, a combination of clinical and biological factors will be most likely be necessary. Prospective and larger studies with a multidimensional approach are needed.
2021
13
18
1501
1519
Body composition and inflammation impact in non-small cell lung cancer patients treated by first-line immunotherapy / Baldessari, Cinzia; Pecchi, Annarita; Marcheselli, Raffaella; Guaitoli, Giorgia; Bonacini, Riccardo; Valoriani, Filippo; Torricelli, Pietro; Reverberi, Linda; Menozzi, Renata; Pugliese, Giuseppe; Vitale, Maria Giuseppa; Sabbatini, Roberto; Bertolini, Federica; Barbieri, Fausto; Dominici, Massimo. - In: IMMUNOTHERAPY. - ISSN 1750-743X. - 13:18(2021), pp. 1501-1519. [10.2217/imt-2021-0038]
Baldessari, Cinzia; Pecchi, Annarita; Marcheselli, Raffaella; Guaitoli, Giorgia; Bonacini, Riccardo; Valoriani, Filippo; Torricelli, Pietro; Reverberi...espandi
File in questo prodotto:
File Dimensione Formato  
imt-2021-0038 (1).pdf

Accesso riservato

Tipologia: Versione pubblicata dall'editore
Dimensione 2.6 MB
Formato Adobe PDF
2.6 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1254435
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 7
  • ???jsp.display-item.citation.isi??? 6
social impact